20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T2072 | BET bromodomain inhibitor | Epigenetic Reader Domain | |
BET bromodomain inhibitor is a potent BET inhibitor. | |||
T10521 | ODM-207 | BET-IN-4,ODM207 | Epigenetic Reader Domain |
ODM-207 (BET-IN-4) is a potent BRD4 inhibitor. | |||
T39374 | PROTAC BET Degrader-10 | ||
PROTAC BET Degrader-10 (WO2017007612A1, example 37) is a highly efficient and selective small molecule compound designed to degrade BET protein BRD4. PROTAC BET Degrader-10 functions by utilizing specific ligands that co... | |||
T39998 | BET bromodomain inhibitor 1 | ||
BET bromodomain inhibitor 1 is an orally active, selective inhibitor of bromodomain and extra-terminal (BET) proteins. It specifically inhibits BRD4 with an IC50 of 2.6 nM. Additionally, BET bromodomain inhibitor 1 demon... | |||
T10518 | BET-BAY 002 | Others | |
BET-BAY 002 is an effective BET inhibitor and exhibits efficacy in a multiple myeloma model. | |||
T1906 | Molibresib | GSK 525762A,GSK525762,I-BET 762 | Epigenetic Reader Domain |
Molibresib (GSK525762) is an inhibitor of BET proteins (IC50: about 35 nM). | |||
T10522 | BET-IN-6 | Epigenetic Reader Domain | |
BET-IN-6, a ligand with potent and high affinity for inhibiting BRD2/BRD4, plays a crucial role in the synthesis of PROTAC BRD2/BRD4 degrader-1 [1], targeting the protein BRD2/4. | |||
T10520 | BET-IN-2 | Epigenetic Reader Domain | |
BET-IN-2 is a BET inhibitor (IC50: 52 nM for BRD4-BD1). | |||
T12559 | PROTAC BET degrader-2 | Others | |
PROTAC BET degrader-2 is a highly potent degrader of Bromodomain and Extra-Terminal (BET) proteins (IC50 of 9.6 nM ). | |||
T13849 | PROTAC BET Degrader-1 | Epigenetic Reader Domain | |
PROTAC BET Degrader-1 is a potent degrader of BET based on PROTAC. | |||
T13850 | PROTAC BET degrader-3 | Epigenetic Reader Domain | |
PROTAC BET Degrader-3 is a potent degrader OF BET based on PROTAC. | |||
T10517 | BET-BAY 002 (S enantiomer) | Others | |
The S-enantiomer of BET-BAY 002, referred to as BET-BAY 002 S enantiomer, is a potent inhibitor of BET (Bromodomain and Extra-Terminal motif proteins). | |||
T12557 | PROTAC BET-binding moiety 1 | Others | |
PROTAC BET-binding moiety 1 is a key intermediate in the synthesis of high affinity BET inhibitors | |||
T12558 | PROTAC BET-binding moiety 2 | Others | |
PROTAC BET-binding moiety 2 is an BET bromodomain inhibitor. | |||
T9619 | I-BET567 | ||
I-BET567, a potent pan-BET inhibitor with oral activity, demonstrates pIC50 values of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. This compound has exhibited efficacy in mouse models of oncology and inflammation [1]. | |||
T62055 | NVS-BET-1 | ||
NVS-BET-1 is a BET bromodomain inhibitor. NVS-BET-1 can regulate keratinocyte plasticity. | |||
T61795 | BET-IN-9 | ||
BET-IN-9 is a BET inhibitor[1]. | |||
T62275 | BET-IN-8 | ||
BET-IN-8 (Compound 27) is a potent inhibitor of BET (Ki: 0.83 μM, Kd: 0.571 μM), which ameliorates LPS-induced sepsis in vivo.BET-IN-8 has shown potential in sepsis. | |||
T2120 | I-BET151 | GSK1210151A | Epigenetic Reader Domain |
I-BET151 (GSK1210151A) (GSK1210151A) is a specific BET inhibitor for BRD2/3/4 (IC50: 0.5/0.25/0.79 μM, in cell-free assays). | |||
T79610 | BET-IN-17 | Epigenetic Reader Domain | |
BET-IN-17, also known as compound 16, serves as a pan-inhibitor for BET, exhibiting inhibitory potencies (pIC50) of 7.8 for BET BD1 and 7.6 for BET BD2 [1]. |